Gibson, C.MacLennan, A.Janssen, N.Kist, W.Hague, W.Haan, E.Goldwater, P.Priest, K.Dekker, G.2007-01-162007-01-162006American Journal of Obstetrics and Gynecology, 2006; 194(4):947e1-947e100002-93781097-6868http://hdl.handle.net/2440/23154Objective: The purpose of this study was to investigate associations between fetal inherited thrombophilia and adverse pregnancy outcomes, including pregnancy-induced hypertensive disorders (PIHD), antepartum hemorrhage (APH), small-for-gestational age <10th percentile (SGA), and preterm birth (PTB). Study design: Seven hundred and seventeen cases and 609 controls were genotyped for Factor V Leiden (FVL, G1691A), Prothrombin gene mutation (PGM, G20210A), and Methylenetetrahydrofolate reductase (MTHFR) C677T and MTHFR A1298C using DNA from newborn screening cards. Results: For babies born <28 weeks' gestation, PGM was associated with an increased risk of SGA (OR 6.40, 95%CI 1.66-24.71) and APH with SGA (OR 6.35, 95%CI 1.63-24.75). Homozygous MTHFR A1298C was associated with an increased risk of SGA for babies born 28-31 weeks gestation (OR 4.00, 95%CI 1.04-15.37), and with APH and SGA for babies born <32 weeks' gestation (OR 3.57, 95%CI 1.09-11.66). Homozygous MTHFR C677T was associated with a reduced risk of PTB and SGA (OR 0.52, 95%CI 0.28-0.96) for babies born 32 to 36 weeks' gestation. Homozygous FVL decreased the risk of PTB <32 weeks' gestation (OR 0.55, 95%CI 0.31-0.98). Conclusion: Fetal thrombophilic polymorphisms may be related to adverse pregnancy outcomes, in particular SGA.en© Mosby, Inc.Fetal thrombophiliaPolymorphismsAdverse pregnancy outcomesJournal article002006038910.1016/j.ajog.2006.01.1110002365968000082-s2.0-3364584603253012Hague, W. [0000-0002-5355-2955]Haan, E. [0000-0002-7310-5124]Goldwater, P. [0000-0003-4822-8488]Dekker, G. [0000-0002-7362-6683]